GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Digipath Inc (OTCPK:DIGP) » Definitions » Price-to-Owner-Earnings

Digipath (Digipath) Price-to-Owner-Earnings : 3.14 (As of Apr. 29, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Digipath Price-to-Owner-Earnings?

As of today (2024-04-29), Digipath's share price is $0.03143. Digipath's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.01. It's Price-to-Owner-Earnings for today is 3.14.


The historical rank and industry rank for Digipath's Price-to-Owner-Earnings or its related term are showing as below:

DIGP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2   Med: 9.75   Max: 23.5
Current: 5.24

During the past 13 years, the highest Price-to-Owner-Earnings of Digipath was 23.50. The lowest was 2.00. And the median was 9.75.


DIGP's Price-to-Owner-Earnings is ranked better than
89.71% of 68 companies
in the Medical Diagnostics & Research industry
Industry Median: 25.575 vs DIGP: 5.24

As of today (2024-04-29), Digipath's share price is $0.03143. Digipath's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Digipath's PE Ratio for today is 7.86.

As of today (2024-04-29), Digipath's share price is $0.03143. Digipath's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.01. Therefore, Digipath's PE Ratio without NRI for today is At Loss.


Digipath Price-to-Owner-Earnings Historical Data

The historical data trend for Digipath's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Digipath Price-to-Owner-Earnings Chart

Digipath Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 7.40

Digipath Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 7.40 6.67

Competitive Comparison of Digipath's Price-to-Owner-Earnings

For the Diagnostics & Research subindustry, Digipath's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Digipath's Price-to-Owner-Earnings Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Digipath's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Digipath's Price-to-Owner-Earnings falls into.



Digipath Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Digipath's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.03143/0.01
=3.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Digipath  (OTCPK:DIGP) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Digipath Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Digipath's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Digipath (Digipath) Business Description

Traded in Other Exchanges
N/A
Address
6450 Cameron Street, Suite 113, Las Vegas, NV, USA, 89118
DigiPath Inc is engaged in providing pharmaceutical-grade analysis and testing cannabis education and training and brings unbiased cannabis news coverage to the cannabis industry. It screens medicinal cannabis for potentially harmful contaminants, including solvents, pesticides, mold and yeast, heavy metals such as mercury, arsenic, cadmium, and others. It also tests cannabis for its quality, potency, and cannabinoid and terpene profiles, which determine the suitability of specific cannabis strains for the treatment of specific ailments.
Executives
A Stone Douglass director 10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank director 19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda officer: Chief Executive Officer 111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann director 1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben director 430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser director 4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer director 287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco director 611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson officer: Chief Financial Officer 3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner director 28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc 10 percent owner 16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin director, officer: President C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee 10 percent owner 3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen director, 10 percent owner, officer: CFO 8908 SPLITARROW DRIVE, AUSTIN TX 78717